Universal antioxidant
Unlike most antioxidants, ALA and its reduced form DHLA are active in both aqueous and lipid environments, and can regenerate other antioxidants including vitamins C and E, CoQ10, and glutathione from their oxidized forms.
Diabetic neuropathy relief
Strongest clinical evidence: 600 mg/day ALA significantly reduces symptoms of peripheral diabetic neuropathy (pain, burning, numbness) in multiple RCTs, with therapeutic approval in Germany.
Insulin sensitivity
ALA activates GLUT4 glucose transporter translocation via PI3K and AMPK pathways, improving skeletal muscle glucose uptake. RCTs show reductions in fasting glucose and HOMA-IR.
Glutathione recycling
DHLA (reduced ALA) reduces oxidized glutathione (GSSG) back to active GSH, effectively amplifying the body's endogenous antioxidant capacity.
Mitochondrial cofactor activity
ALA is an essential cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase — key enzyme complexes in the TCA cycle at the center of mitochondrial energy metabolism.
Nrf2 pathway activation
ALA activates the Nrf2-Keap1 pathway, inducing transcription of antioxidant response element (ARE) genes including glutathione peroxidase, superoxide dismutase, and heme oxygenase-1.
Metal chelation
ALA chelates redox-active metals (iron, copper, cadmium, mercury), preventing them from participating in Fenton reactions that generate hydroxyl radicals — particularly relevant in heavy metal toxicity.
RCT of oral ALA (600 mg/day) vs. placebo in 181 diabetic patients with peripheral neuropathy for 5 weeks.
181 diabetic adults with confirmed peripheral neuropathy. 5-week intervention.
ALA significantly reduced Total Symptom Score (pain, burning, paresthesia, numbness). Clinically meaningful symptom relief. Basis for therapeutic approval in Germany.
RCT of 300 mg/day ALA vs. placebo in obese patients with metabolic syndrome for 8 weeks.
36 adults with metabolic syndrome. 8-week intervention.
Significant reductions in fasting glucose, HOMA-IR, and waist circumference vs. placebo. ALA group also showed reduced CRP and improved lipid profile.